Working...
ClinicalTrials.gov
ClinicalTrials.gov Menu

Varenicline Treatment of Alcohol Dependence in Smokers

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT01553136
Recruitment Status : Completed
First Posted : March 13, 2012
Results First Posted : February 12, 2018
Last Update Posted : November 8, 2018
Sponsor:
Collaborator:
Columbia University
Information provided by (Responsible Party):
Yale University

Brief Summary:
The purpose of this study is to determine whether varenicline is effective in the treatment of alcohol dependence in smokers.

Condition or disease Intervention/treatment Phase
Alcoholism Alcohol Abuse Smoking Alcohol Drinking Drug: Varenicline Phase 2

Detailed Description:
Building upon knowledge about the role of nicotinic acetylcholine receptors in alcohol drinking and smoking, varenicline, a smoking cessation treatment that targets these receptors, will be tested as a potential treatment for alcohol dependent smokers seeking alcohol treatment.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 131 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Triple (Participant, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: 1/2-Multi-site Study: Varenicline Treatment of Alcohol Dependent Smokers
Study Start Date : September 2012
Actual Primary Completion Date : May 2016
Actual Study Completion Date : May 2016

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
Placebo Comparator: Sugar pill Drug: Varenicline
0.5 mg once per day for Days 1 to 3, 0.5 mg twice per day for Days 4 to 7, then two 0.5 mg tablets (1 mg) twice per day
Other Name: Chantix

Active Comparator: Varenicline Drug: Varenicline
0.5 mg once per day for Days 1 to 3, 0.5 mg twice per day for Days 4 to 7, then two 0.5 mg tablets (1 mg) twice per day
Other Name: Chantix




Primary Outcome Measures :
  1. Percentage of Heavy Drinking Days During the Last 8 Weeks of Treatment [ Time Frame: weeks 9-12 ]
    The percentage of days of heavy drinking will be examined over the final 8 weeks of the study averaged by month (weeks 9-12 and weeks 13-16). A heavy drinking day is defined as 5 or more standard drinks for men and 4 or more standard drinks for women. A standard drink contains approximately 0.6 fluid ounces of pure alcohol.

  2. Percentage of Heavy Drinking Days During the Last 8 Weeks of Treatment [ Time Frame: weeks 13-16 ]
    The percentage of days of heavy drinking will be examined over the final 8 weeks of the study averaged by month (weeks 9-12 and weeks 13-16). A heavy drinking day is defined as 5 or more standard drinks for men and 4 or more standard drinks for women. A standard drink contains approximately 0.6 fluid ounces of pure alcohol.

  3. Percentage of Heavy Drinking Days During the Last 8 Weeks of Treatment [ Time Frame: 8 weeks ]
    The percentage of days of heavy drinking will be examined over the final 8 weeks of the study. A heavy drinking day is defined as 5 or more standard drinks for men and 4 or more standard drinks for women. A standard drink contains approximately 0.6 fluid ounces of pure alcohol. Presented here is the average of the 8 weeks (reported as week 17 originally).


Secondary Outcome Measures :
  1. Smoking Abstinence [ Time Frame: Weeks 13-16 ]
    Smoking abstinence is defined by self-reported abstinence from smoking for the last four weeks of treatment (weeks 13-16) and a urine cotinine level less than 15ng/mL measured at week 17.

  2. Drinking Related Consequences [ Time Frame: End of treatment (Week 17) ]
    A self-report measure of negative consequences from drinking will be administered and the total score are analyzed. The ImBIBe, a measure of alcohol consequences based on the Drinker Inventory of Consequences (DRINC) was used. The DRINC total score has a range from 0-45, 45 being the highest score (or greatest number of negative consequences).



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 70 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • are 18 - 70 years of age and seeking treatment of alcohol drinking;
  • meet DSM-IV TR Criteria for Alcohol Dependence
  • report smoking 100 cigarettes or more in their lifetime and currently smoke at least twice weekly on average in the past 90 days and have a urinary cotinine level of > 30ng/mL by semi-quantitative urinalysis or equivalent plasma cotinine level (> 6 ng/mL);
  • report heavy drinking on at least 2 days on average per week (i.e., ≥ 4 drinks on an occasion for women and ≥ 5 drinks for men) for the past 90 days and no more than 7 consecutive days of abstinence at intake.

Exclusion Criteria:

  • exhibit current, clinically significant physical disease or abnormality based on medical history, physical examination, or routine laboratory evaluation including:

    • any unexplained elevations in liver enzymes (i.e., transaminases, bilirubin)
    • clinically significant, unstable cardiovascular disease/uncontrolled hypertension
    • hepatic or renal impairment
    • severe obstructive pulmonary disease
    • diabetes mellitus requiring insulin or certain oral medications (i.e., sulfonylureas) and an A1C hemoglobin test score of > 7 for participants not prescribed these medications
    • baseline systolic blood pressure higher than 150 mm Hg or diastolic blood pressure higher than 95 mm Hg
  • have a history of cancer (except treated basal cell or squamous cell carcinoma of the skin)
  • have a history of serious hypersensitivity reactions or skin reactions to varenicline;
  • exhibit serious psychiatric illness (i.e., schizophrenia, bipolar disorder, severe major depression, panic disorder, borderline personality disorder, organic mood or mental disorders by history or psychological examination
  • report current suicidal ideation (past 6 months) or lifetime hx of suicidal behavior assessed with the Columbia Suicide Severity Rating Scale 60; or risk for aggression using a cut-off of 15 or more on the Overt Aggression Scale - Modified Aggression Scale or 6 or more on the OAS-M Irritability Subscale 61.
  • have used any psychotropic drug in the past month, except individuals who are on a stable dose of a Selective Serotonin Reuptake Inhibitor for at least two months or who report occasional use of prescription sleep aids that they are willing to discontinue;
  • have a current DSM-IV diagnosis of drug dependence other than nicotine or alcohol
  • are at risk for an alcohol withdrawal syndrome as evidenced by:

    • a history of seizures, delirium, or hallucinations during alcohol withdrawal
    • a Clinical Institute Withdrawal Assessment scale 62 score of > 8,
    • report drinking to avoid withdrawal symptoms
    • have required medical treatment of alcohol withdrawal within the past 6 months
  • have used another investigational drug within 30 days or have used medications to treat alcohol (e.g., naltrexone, topiramate, acamprosate, disulfiram) or nicotine use (e.g., clonidine, varenicline, bupropion, nicotine replacement) in the past 3 months or intend to use these medications;prior use of nicotine replacement in situations where smoking is not permitted (e.g., planes) without the intention to quit smoking is not exclusionary;
  • intend to donate blood or blood products during the treatment phase of the study
  • have a Body Mass Index (calculated as weight in kilograms divided by the square of height in meters) less than 15 or greater than 39.99 or weight less than 45 kg;
  • are a female of childbearing potential who is pregnant, nursing, or not practicing effective contraception (oral, injectable, or implantable contraceptives, intrauterine device, or barrier method with spermicide).

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01553136


Locations
Layout table for location information
United States, Connecticut
Connecticut Mental Health Center - Substance Abuse Treatment Unit
New Haven, Connecticut, United States, 06511
United States, New York
Parallax Center
New York, New York, United States, 10016
Sponsors and Collaborators
Yale University
Columbia University
Investigators
Layout table for investigator information
Principal Investigator: Stephanie O'Malley, PhD Yale University
Principal Investigator: Allen Zweben, PhD Columbia University

Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Layout table for additonal information
Responsible Party: Yale University
ClinicalTrials.gov Identifier: NCT01553136     History of Changes
Other Study ID Numbers: 1106008598
First Posted: March 13, 2012    Key Record Dates
Results First Posted: February 12, 2018
Last Update Posted: November 8, 2018
Last Verified: October 2018

Keywords provided by Yale University:
alcohol-related disorders
Cholinergic Drugs
varenicline
Chantix

Additional relevant MeSH terms:
Layout table for MeSH terms
Varenicline
Alcoholism
Alcohol Drinking
Alcohol-Related Disorders
Substance-Related Disorders
Chemically-Induced Disorders
Mental Disorders
Drinking Behavior
Ethanol
Anti-Infective Agents, Local
Anti-Infective Agents
Central Nervous System Depressants
Physiological Effects of Drugs
Nicotinic Agonists
Cholinergic Agonists
Cholinergic Agents
Neurotransmitter Agents
Molecular Mechanisms of Pharmacological Action